Document is current
Any future updates will be listed below
-
Authors
Turaga, Soumya M. https://orcid.org/0000-0002-1933-2764
Hembruff, Stacey L. https://orcid.org/0009-0006-3224-4773
Savelieff, Masha G. https://orcid.org/0000-0001-5575-2494
Ghosh, Arnab https://orcid.org/0000-0003-0355-7763
Puri, Rajni V. https://orcid.org/0000-0002-0570-7350
Pathak, Harsh B. https://orcid.org/0000-0003-4034-0520
Paradiso, Linda J. https://orcid.org/0009-0008-6314-1659
Myers, Thomas J. https://orcid.org/0009-0000-1008-8710
Li, Ao https://orcid.org/0009-0004-4508-5367
Godwin, Andrew K. https://orcid.org/0000-0002-3987-9580
-
Funding
Funding for this research was provided by:
Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health (P20GM130423)
National Cancer Institute, NIH (RO1CA260132)
University of Pennsylvania Basser Center for BRCA External Grant Program Innovation Award
Honorable Tina Brozman Foundation
OVERRUN Ovarian Cancer Foundation
VITRAC Therapeutics
Chancellors Distinguished Chair in Biomedical Sciences Endowed Professor (AKG).
- License Information
-
More Information
Article History
Received: 30 January 2025
Accepted: 24 February 2025
First Online: 26 March 2025
Declarations
:
: LJP and TJM are employees of VITRAC Therapeutics, LLC. AKG reports research funding from Predicine and VITRAC Therapeutics, is a co-founder of Sinochips Diagnostics, and serves as a scientific advisory board member to Biovica, Clara Biotech, and Sinochips Diagnostics. The remaining authors report no conflicts of interest.
: All studies were approved by the Institutional Animal Care and Use Committee.
